UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 22, 2018
KALVISTA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
|
||
|
Delaware |
|
001-36830 |
|
20-0915291 |
||
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
||
|
|
|
|
||||
|
55 Cambridge Parkway Suite 901E Cambridge, Massachusetts |
||||||
|
(Address of Principal Executive Offices) (Zip Code)
|
||||||
(857) 999-0075
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
||
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
|
|||
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
|||
(b)
On September 22, 2018, Joshua Resnick, M.D. (“Dr. Resnick”) advised the Board of Directors (the “Board”) of KalVista Pharmaceuticals, Inc. (the “Company”) that he would resign as a Class I independent director of the Company and as a member of the Compensation Committee of the Board, effective September 29, 2018. Dr. Resnick’s resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. Following Dr. Resnick’s resignation, the size of the Board was reduced by one member to five members and Richard Aldrich was appointed to the Compensation Committee.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
KALVISTA PHARMACEUTICALS, INC. |
||
|
|
|
|
|
By: |
|
/s/ Benjamin L. Palleiko |
|
Name: |
|
Benjamin L. Palleiko |
|
Title: |
|
Chief Financial Officer |
Date: September 26, 2018